Eurofins Medical Device Testing Risk Report

🛡️ Financial & Liquidity

Eurofins Medical Device Testing has achieved significant financial milestones, indicating a strong performance in recent years. The company's revenue growth and profitability trends demonstrate resilience, particularly in the post-COVID landscape.

• Eurofins achieved a new record level of annual revenues and demonstrated a potent increase in margins and cash generation 🗓 January 30, 2025.
• The firm confirmed its profitability and cash flow objectives for 2024, despite challenges from the post-COVID reset of biopharma pipelines 🗓 October 22, 2024.
• Eurofins reported new record revenues and robust margins and cash flow growth for the first half of 2024 🗓 July 24, 2024.

📜 Innovation & R&D

The company continues to expand its testing capabilities and facilities, showcasing its commitment to innovation within the medical device testing sector. This growth is evident through acquisitions and collaborations that enhance their service potential.

• Eurofins announced the successful acquisition of Synlab's clinical diagnostics operations in Spain, expanding its diagnostic capabilities 🗓 April 1, 2025.
• The expansion of the Eurofins E&E and ETS-Lindgren Silicon Valley EMC testing facility highlighted significant growth in their innovation infrastructure 🗓 February 29, 2024.
• The acquisition of Infinity Laboratories, Inc. further expanded Eurofins' biopharma product testing offerings in the United States 🗓 September 16, 2024.

⚖️ Legal & Regulatory

Eurofins has been proactive in managing its regulatory landscape, recruiting experienced professionals to lead regulatory toxicology efforts. This move positions them well to navigate the complex regulatory environment of the medical device sector.

• The company named a new North American head of regulatory toxicology 🗓 July 8, 2025.
• Eurofins recruited a former WuXi AppTec executive to bolster its regulatory role 🗓 July 9, 2025.